Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

This study is testing two different drug combinations — golidocitinib with either a chemotherapy drug (mitoxantrone hydrochloride liposome) or a targeted drug (chidamide) — for people with peripheral T-cell lymphoma (a type of aggressive blood cancer) that has come back or not responded to previous treatment. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with peripheral T-cell lymphoma that has relapsed or not responded to prior treatment - You have at least one measurable area of cancer - You are in reasonably good physical health (ECOG 0–2) - Your organs and bone marrow are functioning adequately - You have a life expectancy of more than 12 weeks **You may NOT be eligible if...** - You have a rare serious condition called hemophagocytic lymphohistiocytosis (HLH, where the immune system attacks the body) - Your lymphoma has spread to the brain or spinal cord - You have an active uncontrolled infection - You have serious uncontrolled heart problems - You take certain medications that strongly interact with the study drugs (CYP3A inhibitors/inducers or blood thinners) - You have HIV/AIDS Talk to your doctor to see if this trial is right for you.